Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial

Thomas Lodise, Joe Yang, Laura A Puzniak, Ryan Dillon, Marin Kollef, Thomas Lodise, Joe Yang, Laura A Puzniak, Ryan Dillon, Marin Kollef

Abstract

Introduction: Hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP) are associated with significant healthcare resource utilization (HCRU). This a priori, exploratory, secondary analysis from the ASPECT-NP clinical trial evaluated resource utilization among patients with ventilated HABP (vHABP)/VABP treated with ceftolozane/tazobactam or meropenem.

Methods: This analysis used data from the randomized, double-blind, noninferiority phase 3 ASPECT-NP trial of patients with vHABP/VABP randomized to receive ceftolozane/tazobactam 3 g (ceftolozane 2 g/tazobactam 1 g) or meropenem 1 g for 8-14 days. Day 28 outcomes included hospital length of stay (LOS), intensive care unit (ICU) LOS, and time to mechanical ventilation extubation in the microbiological intention-to-treat (mITT) population and in an HCRU population. The HCRU population, a subset of patients from the mITT population that were alive at day 28, was used to remove resource use bias influenced by mortality rates.

Results: Ceftolozane/tazobactam-treated versus meropenem-treated patients, respectively, had fewer deaths (20.1% vs. 25.5%), fewer hospital discharges (30.7% vs. 32.4%), and higher ICU discharges (60.0% vs. 58.3%) and extubations (51.9% vs. 48.2%) by day 28. In the HCRU population, adjusted LOS differences (95% confidence intervals) for ceftolozane/tazobactam compared with meropenem were 0.1 (- 1.4 to 1.6) hospitalization days, - 1.4 (- 2.9 to 0.2) ICU days, and - 0.9 (- 2.4 to 0.7) mechanical ventilation days. Patterns were similar among the VABP and Pseudomonas aeruginosa subgroups.

Conclusion: Similar 28-day resource utilization outcomes were observed between ceftolozane/tazobactam and meropenem in the mITT population of patients from ASPECT-NP with vHABP/VABP due to gram-negative pathogens. ASPECT-NP was not powered to detect differences in resource utilization outcomes between treatment groups; however, numerical differences in ICU LOS and duration of mechanical ventilation were noted. Further study is needed to assess resource utilization in the real-world practice setting, especially among patients excluded from ASPECT-NP, including those with resistant P. aeruginosa infections.

Trial registrations: ClinicalTrials.gov: NCT02070757, registered February 25, 2014; EudraCT: 2012-002862-11.

Keywords: Ceftolozane/tazobactam; Hospital-acquired bacterial pneumonia; Hospitalization; Mechanical ventilation; Meropenem; Multidrug resistance; Pseudomonas aeruginosa; Ventilator-associated bacterial pneumonia.

References

    1. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–e111. doi: 10.1093/cid/ciw353.
    1. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51(suppl 1):S81–S87. doi: 10.1086/653053.
    1. Sader HS, Castanheira M, Flamm RK. Antimicrobial activity of ceftazidime-avibactam against gram-negative bacteria isolated from patients hospitalized with pneumonia in US medical centers, 2011 to 2015. Antimicrob Agents Chemother. 2017;61(4):e02083-16. doi: 10.1128/AAC.02083-16.
    1. Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37(11):1288–1301. doi: 10.1017/ice.2016.174.
    1. Frantzeskaki F, Orfanos SE. Treating nosocomial pneumonia: what’s new. ERJ Open Res. 2018;4(2):00058–02018. doi: 10.1183/23120541.00058-2018.
    1. Niederman MS. Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design. Clin Infect Dis. 2010;51(suppl 1):S12–S17. doi: 10.1086/653035.
    1. Ibn Saied W, Mourvillier B, Cohen Y, et al. A comparison of the mortality risk associated with ventilator-acquired bacterial pneumonia and nonventilator ICU-acquired bacterial pneumonia. Crit Care Med. 2019;47(3):345–352. doi: 10.1097/CCM.0000000000003553.
    1. Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol. 2012;33(3):250–256. doi: 10.1086/664049.
    1. Micek ST, Kollef MH, Torres A, et al. Pseudomonas aeruginosa nosocomial pneumonia: impact of pneumonia classification. Infect Control Hosp Epidemiol. 2015;36(10):1190–1197. doi: 10.1017/ice.2015.167.
    1. Muscedere JG, Day A, Heyland DK. Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia. Clin Infect Dis. 2010;51(suppl 1):S120–S125. doi: 10.1086/653060.
    1. Sun D, Moorthy V, Chang S-C, et al. Economic burden of ventilator-associated, hospital-acquired, healthcare-associated and community-acquired pneumonia in the hospital setting [abstract] Open Forum Infect Dis. 2016;3(suppl 1):1494. doi: 10.1093/ofid/ofw172.1196.
    1. O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on Antimicrobial Resistance. 2014;20:1–16. . Accessed 7 Apr 2020
    1. Infectious Diseases Society of America. Spellberg B, Blaser M, et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 2011;52(suppl 5):S397–S428. doi: 10.1093/cid/cir153.
    1. Martin-Loeches I, Torres A, Rinaudo M, et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. J Infect. 2015;70(3):213–222. doi: 10.1016/j.jinf.2014.10.004.
    1. Tabak YP, Merchant S, Ye G, et al. Incremental clinical and economic burden of suspected respiratory infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States. J Hosp Infect. 2019;103(2):134–141. doi: 10.1016/j.jhin.2019.06.005.
    1. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance—the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–1098. doi: 10.1016/S1473-3099(13)70318-9.
    1. Lodise TP, Zhao Q, Fahrbach K, Gillard PJ, Martin A. A systematic review of the association between delayed appropriate therapy and mortality among patients hospitalized with infections due to Klebsiella pneumoniae or Escherichia coli: how long is too long? BMC Infect Dis. 2018;18(1):625. doi: 10.1186/s12879-018-3524-8.
    1. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015;40(4):277–283.
    1. Bonine NG, Berger A, Altincatal A, et al. Impact of delayed appropriate antibiotic therapy on patient outcomes by antibiotic resistance status from serious gram-negative bacterial infections. Am J Med Sci. 2019;357(2):103–110. doi: 10.1016/j.amjms.2018.11.009.
    1. ZERBAXA® (ceftolozane and tazobactam) for injection, for intravenous use. Prescribing information. Whitehouse Station, NJ: Merck Sharpe & Dohme Corp. 2020.
    1. Moya B, Zamorano L, Juan C, Ge Y, Oliver A. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54(9):3933–3937. doi: 10.1128/AAC.00296-10.
    1. Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74(1):31–51. doi: 10.1007/s40265-013-0168-2.
    1. Shortridge D, Pfaller MA, Castanheira M, Flamm RK. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013–2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program. Diagn Microbiol Infect Dis. 2018;92(2):158–163. doi: 10.1016/j.diagmicrobio.2018.05.011.
    1. Kollef MH, Nováček M, Kivistik Ü, et al. Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19(12):1299–1311. doi: 10.1016/S1473-3099(19)30403-7.
    1. Rice LB. Antimicrobial stewardship and antimicrobial resistance. Med Clin N Am. 2018;102(5):805–818. doi: 10.1016/j.mcna.2018.04.004.
    1. Verburg IW, de Keizer NF, de Jonge E, Peek N. Comparison of regression methods for modeling intensive care length of stay. PLoS One. 2014;9(10):e109684. doi: 10.1371/journal.pone.0109684.
    1. Austin PC, Rothwell DM, Tu JV. A comparison of statistical modeling strategies for analyzing length of stay after CABG surgery. Health Serv Outcomes Res Method. 2002;3(2):107–133. doi: 10.1023/A:1024260023851.
    1. Kanzaria HK, Probst MA, Ponce NA, Hsia RY. The association between advanced diagnostic imaging and ED length of stay. Am J Emerg Med. 2014;32(10):1253–1258. doi: 10.1016/j.ajem.2014.07.038.
    1. Pedan A. Analysis of count data using the SAS system. In: Proceedings of the 26th Annual SAS Users Group International Conference; 2001.
    1. Drummond M, O’Brien B. Clinical importance, statistical significance and the assessment of economic and quality-of-life outcomes. Health Econ. 1993;2(3):205–212. doi: 10.1002/hec.4730020303.
    1. Brock GN, Barnes C, Ramirez JA, Myers J. How to handle mortality when investigating length of hospital stay and time to clinical stability. BMC Med Res Methodol. 2011;11:144. doi: 10.1186/1471-2288-11-144.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe